Compare ECVT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECVT | CRVS |
|---|---|---|
| Founded | 1935 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2017 | 2016 |
| Metric | ECVT | CRVS |
|---|---|---|
| Price | $10.39 | $14.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $14.00 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 1.2M | 800.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $723,515,000.00 | N/A |
| Revenue This Year | $29.07 | N/A |
| Revenue Next Year | $6.71 | N/A |
| P/E Ratio | $94.45 | ★ N/A |
| Revenue Growth | ★ 2.70 | N/A |
| 52 Week Low | $7.41 | $5.03 |
| 52 Week High | $15.09 | $26.95 |
| Indicator | ECVT | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 61.02 |
| Support Level | $9.67 | $14.24 |
| Resistance Level | $11.31 | $16.66 |
| Average True Range (ATR) | 0.40 | 0.68 |
| MACD | -0.13 | 0.16 |
| Stochastic Oscillator | 14.52 | 86.63 |
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.